12 results about "Antihypertensive medication" patented technology

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

To provide a useful blood pressure elevation suppressant. [Solution] A blood pressure elevation inhibitor containing as an active ingredient one or more compounds selected from the group consisting of saclipin A (a compound represented by the following formula (2)), saclipin B, and derivatives thereof, isolated from an extract of Suizenji Nori. TIFF2026115124000007.tif68169

This invention provides an ACE-inhibiting peptide and its application in health foods and antihypertensive drugs, belonging to the field of ACE-inhibiting peptide technology. The ACE-inhibiting peptide is formed by the sequential condensation of Val-Val-Pro-Pro-Gly-His-His-Pro-Phe, with the amino acid sequence: VVPPGHPF. At the same peptide concentration, the ACE-inhibiting effect is further enhanced when this ACE-inhibiting peptide is mixed with other ACE-inhibiting peptides, and it also has a hypotensive effect on hypertensive mice. The ACE-inhibiting peptide of this invention has a small molecular weight and is easily absorbed, making it a potential natural antihypertensive drug or health food. It also opens up new avenues for the development of black beans and the high-value utilization of processing by-products.

This invention discloses a casein-derived small molecule peptide with antihypertensive effect and its preparation method, belonging to the field of bioactive peptide technology. The preparation method is as follows: S1, mix casein with water and stir until homogeneous; S2, add a complex protease for enzymatic hydrolysis, then add bromelain for further enzymatic hydrolysis to inactivate the enzyme; S3, centrifuge the mixture; S4, heat the separated mixture, add activated carbon for adsorption, then add diatomaceous earth, stir until homogeneous, and filter; S5, further filter through a membrane; S6, concentrate the mixture, sterilize, and dry to obtain the casein-derived small molecule peptide. The casein-derived small molecule peptide of this invention can effectively lower blood pressure by inhibiting ACE activity and blocking the production of angiotensin II. This small molecule peptide significantly increases blood flow activity and angiotensin II content in a hypertensive model zebrafish, exhibiting a dose-dependent effect, achieving the same effect as the antihypertensive drug captopril, and with an efficacy concentration that is half that of the positive control drug.

The application discloses a traditional Chinese medicine formula for treating hypertension and a preparation method thereof, and belongs to the technical field of formula preparation of hypertension and comprises the following raw materials in parts by weight: 5-15 parts of rhubarb, 5-15 parts of dried ginger, 5-15 parts of oyster shell, 5-15 parts of oyster, 5-15 parts of cassia twig, 5-15 parts of white peony root, 5-15 parts of prepared rehmannia root and 5-15 parts of mountain yam. In the application, the core compatibility of Feng Yin decoction, Liuwei Dihuang decoction, Taohong Siwu decoction and Huanglian Jiedu decoction is fused, the five effects of 'calming liver and suppressing yang, nourishing yin and kidney, promoting blood circulation and removing blood stasis, clearing heat and resolving toxin and invigorating spleen and stomach' are considered, the pathogenesis of 'deficiency in origin and excess in superficiality' of hypertension is adjusted as a whole, compared with existing western medicines, the drug has stable and long-acting effect, can effectively reduce blood pressure, can significantly improve dizziness, headache, chest distress and other accompanying symptoms, can reduce the dependence of patients on chemical antihypertensive drugs and side effects such as liver and kidney damage and electrolyte disturbance caused by the chemical antihypertensive drugs, and is especially suitable for long-term taking of middle-aged and old patients and patients with combined basic diseases.

This invention discloses a turtle peptide with angiotensin-converting enzyme (ACE) inhibitory activity, its preparation, and its application, belonging to the field of biotechnology. Using turtle as raw material, this invention obtains peptide components with a molecular weight less than 5 kDa through enzymatic hydrolysis and ultrafiltration. Sequencing reveals three peptide sequences with ACE inhibitory activity: AAGPAGGNLN, EAGAQGPPGA, and GARGDK. In vitro activity experiments verified the ACE inhibitory function of the three turtle peptides. The turtle peptide combination prepared by this invention exhibits significant ACE inhibitory activity and can be used to develop functional foods or antihypertensive drugs. Furthermore, the preparation method is environmentally friendly, efficient, and suitable for industrial production.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the concentration of the antihypertensive drug losartan in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The mobile phase of the LC comprises an aqueous formic acid solution and acetonitrile; the elution program of the LC includes: 60-80% acetonitrile by volume in the mobile phase for 0-1.4 min; and a flow rate of 0.6-1 mL / min. This invention provides a highly efficient and accurate method for detecting losartan drug concentration, enabling precise determination of the losartan concentration in plasma and ensuring the accuracy and reliability of the data.

The present invention relates to the pharmaceutical technology. Keratin CF2, methods for producing the same, pharmaceutical compositions containing the same and the use thereof are disclosed, and the present invention particularly relates to keratin CF2, nucleic acid molecules encoding the keratin CF2, expression vectors containing the nucleic acid molecule, host cells containing the expression vector or in which the nucleic acid molecule is incorporated into the genome, methods for producing the keratin CF2, pharmaceutical compositions containing the keratin CF2, and the use of the keratin CF2, nucleic acid molecules, expression vectors, host cells or pharmaceutical compositions in the manufacture of antipyretics, analgesics, antitussives, expectorants, anticonvulsants, antiepileptics, antihypertensives, anti-inflammatorys or antivirals.

A method for diagnosing or predicting preeclampsia in a pregnant woman or determining whether a pregnant woman is at risk of developing preeclampsia is provided, comprising: a) obtaining at least one (such as two or more) maternal or fetal parameter or factor of the pregnant woman selected from the group comprising: (i) one or more of mean arterial pressure, BMI at sampling, ΔBMI, gestational age, and ΔBMI / GA; (ii) maternal age; (iii) one or more of urinary protein level and ratio of urinary protein level (such as total urinary protein) to urinary creatinine level; (iv) one or more of history of preeclampsia in previous pregnancies and having received antihypertensive medication; and (v) any combination of (i)-(iv), b) determining whether the pregnant woman has misfolded proteins or misfolded protein aggregates in her urine, and c) combining the at least one maternal or fetal parameter or factor obtained in step a) with the level of misfolded proteins or misfolded protein aggregates in the pregnant woman's urine to diagnose or predict preeclampsia or determine the risk of preeclampsia.

The application discloses a preparation method of grifola frondosa protease hydrolysate and a blood pressure reducing polypeptide and application thereof. The sequence of the blood pressure reducing polypeptide is APPLRP, LPPLL, LPPLLL, LPPLPRP, LPPPLLK, LPPRLP, LPPRP or RPPLP, the blood pressure reducing polypeptide is an ACE targeted peptide, and is derived from grifola frondosa protease hydrolysate. The hexapeptide and heptapeptide with the blood pressure reducing function provided by the application can inhibit ACE activity, treat hypertension, are safe and easy to absorb, have no side effects, can be used for preparation or screening of antihypertensive drugs, and have a good application prospect.

1. Name of the designed product: packing box (sandalwood antihypertensive medicinal tea). 2. Use of the designed product: packing for medicinal tea. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

This invention provides an ACE-inhibiting peptide and its application in health foods and antihypertensive drugs, belonging to the field of ACE-inhibiting peptide technology. The ACE-inhibiting peptide is formed by the sequential condensation of Asp-Thr-Phe-Pro-Tyr-Pro-Arg, with the amino acid sequence DTFPYPR. At the same peptide concentration, the ACE-inhibiting effect is further enhanced when this ACE-inhibiting peptide is mixed with other ACE-inhibiting peptides, and it also has a hypotensive effect on hypertensive mice. The ACE-inhibiting peptide of this invention has a small molecular weight and is easily absorbed, making it a potential natural antihypertensive drug or health food. It also opens up new avenues for the development of black beans and the high-value utilization of processing by-products.